Federated Hermes Inc. Sells 183,401 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Federated Hermes Inc. reduced its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 89.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,428 shares of the biopharmaceutical company’s stock after selling 183,401 shares during the quarter. Federated Hermes Inc.’s holdings in Emergent BioSolutions were worth $51,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Quantbot Technologies LP grew its stake in shares of Emergent BioSolutions by 218.7% during the third quarter. Quantbot Technologies LP now owns 8,700 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 5,970 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Emergent BioSolutions by 1.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock valued at $1,105,000 after buying an additional 6,724 shares during the last quarter. Laurion Capital Management LP bought a new position in shares of Emergent BioSolutions during the third quarter valued at about $37,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Emergent BioSolutions by 0.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,246,020 shares of the biopharmaceutical company’s stock valued at $4,236,000 after buying an additional 11,573 shares during the last quarter. Finally, CoreCap Advisors LLC bought a new position in shares of Emergent BioSolutions during the fourth quarter valued at about $33,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Price Performance

EBS stock opened at $3.98 on Tuesday. The firm has a 50 day moving average price of $2.50 and a 200-day moving average price of $2.25. Emergent BioSolutions Inc. has a 52-week low of $1.42 and a 52-week high of $10.88. The firm has a market capitalization of $208.29 million, a price-to-earnings ratio of -0.36 and a beta of 1.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.08.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The business had revenue of $300.40 million during the quarter. During the same period last year, the firm posted ($3.17) EPS. Equities research analysts forecast that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Benchmark reissued a “buy” rating and issued a $5.00 target price on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.